Astrocyteendothelial interactions at the bloodbrain barrier
Protocols Dosing and schedules are set based on body weight, severity of inflammation, organ involved, and peptide pharmacology
FOXO4-DRI enters senescent cells and competitively binds to p53 through its modified peptide sequence, displacing endogenous FOXO4 and freeing p53 to activate cell death pathways including BAX and PUMA
Participants who were given a higher dose of AOD-9604 (10 mg/day) did not lose more weight
With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide
Scotland has its own system for producing clinical guidelines called the Scottish Intercollegiate Guidelines Network (SIGN)